Methenamine Hippurate Tablets Market Forecast 2026–2030 Highlighting Expansion Across Industries
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Methenamine Hippurate Tablets Market Expected To Scale Between 2026 And 2030?
The methenamine hippurate tablets market size has experienced robust expansion in recent years. This market is projected to expand from $10.11 billion in 2025 to $10.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.4%. Historically, this growth was influenced by factors such as insufficient understanding of recurrent UTI prevention, limited availability of specialized urology services, minimal uptake of antimicrobial tablets, a dependency on hospital-based care, and conventional packaging methods.
The methenamine hippurate tablets market is projected to demonstrate robust growth over the next few years, with its size expected to reach $14.49 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.5%. This expansion during the forecast period is attributable to the increasing incidence of urinary tract infections, a growing demand for outpatient and homecare treatment, technological advancements in tablet formulation, the rising adoption of personalized medicine, and the expansion of online pharmacy channels. Major trends shaping the market in this period include the rising prevalence of recurrent UTIs, growth in the geriatric population, an increasing preference for oral antimicrobial therapies, the expansion of home healthcare services, and the emergence of personalized medication regimens.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9412&type=smp
Which Key Factors Are Driving The Methenamine Hippurate Tablets Market Growth?
The increasing prevalence of urinary tract infections (UTI) is anticipated to stimulate the expansion of the methenamine hippurate tablets market. UTIs are widespread conditions that arise when bacteria enter the urethra and subsequently infect the urinary tract, typically via the skin or rectum. Methenamine hippurate tablets are utilized for either the prevention or treatment of recurrent urinary tract infections attributed to specific bacterial types. As an illustration, the National Health Service, a UK-based government department, reported in October 2023 that the 2022-23 period saw 147,285 admissions where urinary tract infections were the primary diagnosis. Of these, 56% (82,392) were individuals aged 65 or older, with the highest volume of admissions, 17,280, recorded in the 80-84 age group. Thus, the escalating cases of urinary tract infections are serving as a key driver for the methenamine hippurate market’s growth.
Which Segments Define The Methenamine Hippurate Tablets Market Segment Structure?
The methenamine hippurate tablets market covered in this report is segmented –
1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By 20 Tablets per Bottle: Standard Packaging, Bulk Packaging Options
2) By 6 Tablets per Bottle: Standard Packaging, Sample Or Trial Packaging
Which Trends Are Contributing To Changes In The Methenamine Hippurate Tablets Market?
Leading companies within the methenamine hippurate tablets market are forming alliances to enhance their market profitability. A strategic collaboration signifies a deliberate partnership between organizations, aimed at achieving shared goals through synchronized endeavors that capitalize on each other’s strengths and resources. For example, in May 2023, EQL Pharma AB, a pharmaceutical company based in Sweden known for supplying methenamine hippurate tablets, entered into a collaboration with Dr. Pfleger Arzneimittel GmbH. Through this partnership, EQL Pharma AB plans to introduce Methenamine Hippurate under an EQL-registered brand within the upcoming two years, including standard license fees, specific regulatory and reimbursement milestones, and a volume-dependent supply price, pending regulatory approval. Dr. Pfleger Arzneimittel GmbH is a pharmaceutical company based in Germany.
Who Are The Established Players Within The Methenamine Hippurate Tablets Market?
Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.
Get The Full Methenamine Hippurate Tablets Market Report:
https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report
Which Region Accounts For The Largest Portion Of The Methenamine Hippurate Tablets Market?
North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Methenamine Hippurate Tablets Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report
Browse Through More Reports Similar to the Global Methenamine Hippurate Tablets Market 2026, By The Business Research Company
Methenamine Hippurate Tablets Market Report 2026
https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report
Methicillin Resistant Staphylococcus Aureus Mrsa Drugs Market Report 2026
Muscle Relaxant Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
